FDA priority review
Important new treatment for the most common skin cancer (basal cell carcinoma) called Erivedge (vismodegib)
The FDA approved a novel new treatment for the most common kind of skin cancer. The drug is called Erivedge (vismodegib) and treats patients with basal cell carcinoma.
The first of a new kind of lab test and a first-in-the-class therapy have been approved by the FDA. Zelboraf (vemurafenib) was approved by the FDA under the priority review program.